Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials
The New York Times
Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.
More Related News
Set News Language for United States
Primary Language (Mandatory)
Other Language[s] (Optional)
No other language available
Set News Language for World
Primary Language (Mandatory)
Other Language(s) (Optional)
Set News Source for United States
Primary Source (Mandatory)
Other Source[s] (Optional)
Set News Source for World
Primary Source (Mandatory)
Other Source(s) (Optional)